TP53 and breast carcinoma: However, although the number of MTAs (molecular targeted agents) is constantly rising, there is still a lack of drugs targeting many genes, commonly expressed in breast cancer, like TP53 mutations (17% of our patients expressed this alteration) for example, making matching genomic alterations with targeted therapies still a great challenge for the majority of patients and one of the greatest limitations for precision oncology.